Skip to content
Search

Latest Stories

Stock shortage alert: Guanfacine ADHD medication unavailable until May

Stock shortage alert: Guanfacine ADHD medication unavailable until May

While alternative ADHD medications remain accessible according CPE, they "may not meet increased demand"

The Department of Health and Social Care (DHSC) published a notification regarding the shortage of Guanfacine 2mg and 3mg modified-release tablets has raised concerns within the healthcare community.


This critical medicine supply notification, issued on March 28th, projects the unavailability of these tablets until the week commencing May 6, 2024.

Guanfacine tablets, commonly prescribed to alleviate symptoms of hyperactivity and impulsivity while enhancing attention and concentration.

However, the scarcity of these specific strengths poses challenges for patients reliant on this medication.

According to a recent survey conducted by Royal Pharmaceutical Society (RPS) and the Pharmacists Defence Association, "more than a third of pharmacists (35%) said they have seen an increase in patients declining prescriptions in the last 12 months."

The organisation further added, "every day pharmacists are asked by patients who are unable to afford all the items their prescription which ones they could 'do without'."

"Patients shouldn’t have to make choices which involve rationing their medicines. No one should face a financial barrier to getting medicines which a health professional has prescribed as necessary."

In 2021/22, revenue from prescription charges and pre-payment certificates in England totaled £651.9 million. According to an NPA survey, commonly foregone medicines due to the prescription charge include antibiotics, painkillers, asthma inhalers, blood pressure medication, and antidepressants.

Nick Kaye, Chair of the National Pharmacy Association, expressed his discontentment with the revision calling it "a shameful neglect of working people on low fixed incomes".

" As pharmacists, we are health care professionals and have no interest in being tax collectors.”

Several countries across the globe experienced shortages of medications for the treatment of attention deficit hyperactivity disorder (ADHD)including the UK, the US and Australia, last year.

Community Pharmacy England (CPE) has cautioned that while alternative strengths of Guanfacine remain accessible, they may not adequately meet the heightened demand, potentially resulting in treatment interruptions for patients.

Pharmacies are advised to endorse prescriptions for unlicensed products appropriately, ensuring compliance with regulatory guidelines.

In response to the shortage, DHSC and NHSE/I have introduced an online Medicines Supply Tool to furnish real-time updates on medication shortages. This digital platform equips healthcare professionals with crucial information to navigate supply challenges effectively.

Furthermore, pharmacies are urged to report any new shortages not listed on the SPS website using the designated shortage reporting tool, facilitating proactive management of emerging supply issues.

Amidst these challenges, the NHS has unveiled a beacon of hope this week with the launch of an ADHD taskforce which seeks to overhaul ADHD care delivery, aligning with the NHS Long Term Plan's overarching objectives for mental health services.

As the healthcare community navigates these supply challenges and embraces innovative solutions, collaborative efforts are paramount to ensuring uninterrupted access to essential medications and delivering optimal care for patients across the UK.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less